Lower margins for Smith & Nephew’s (NYSE:SNN) bread-and-butter orthopedics division drove the British company’s third-quarter profits down nearly 3 percent for the three months ended Oct. 1.
Smith & Nephew posted profits of $133 million, or 14.9 cents per share, on sales of $1.03 billion for the quarter – a top-line increase of 9.7 percent when compared with the $941 million in revenues reported for the same period last year. But Q3 2010 profits were $137 million, or 15.4 cents per share.
The rub came from a profit margin of 15.6 percent for the workhorse ortho division, compared with a 22.2 percent margin for Q3 2010. Smith & Nephew chalked the decline up to three factors:
Sign up to get our free newsletters delivered right to your inbox
"First, we continued to experience pressure on the gross margin from the sales mix, a trend seen in the first half of the year. Top line growth was driven by products and geographies where we achieved lower margins, reducing the gross profit margin by about 200 basis points," according to a press release. "Second, orthopaedics experienced an unusually high level of periodic costs – legal, inventory and receivables – in the quarter, totaling about $10 million.
"Finally, it is clear that the modest growth and continuing pricing pressures in established markets necessitate a lower orthopaedics cost base. Actions were underway to address this, but these have not been adequate, resulting in a cost base which was $10 million too high in the quarter. The new combined orthopaedics and endoscopy management team has instigated much tighter controls over spending and we are confident that the orthopaedics margin will improve materially from Q4 onwards."
The margin slide prompted CEO Olivier Bohuon to say he’s "disappointed with our margin performance, with orthopaedics overshadowing excellent performances in endoscopy and advanced wound management. We are taking the steps necessary to reduce a cost base in orthopaedics that is too high for ongoing market conditions. I expect to see material improvements from Q4 onwards and am confident that the group will deliver a Q4 trading profit margin above 24 percent," according to a press release.
Smith & Nephew left its revenue guidance unchanged for the rest of year.
SNN shares were trading at $44.02 as of about 1 p.m. today, down roughly 2.8 percent.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
SurModics’ Q4 sales rise, losses narrow
Fourth-quarter sales for SurModics (NSDQ:SRDX) rose 10.3 percent and losses declined by 40.3 percent.
SurModics reported losses of $12.9 million, or 74 cents per share, on sales of $17.2 million for the three months ended Sept. 30.
That compares with losses of $21.7 million, or $1.25 per share, on sales of $15.5 million during the same period last year. Read more
Rochester Medical’s Q4 profits surge on 33% sales increase
Fourth-quarter profits surged 136.7 percent for Rochester Medical (NSDQ:ROCM) on a sales boost of 33.4 percent.
Rochester reported profits of $407,000, or 3 cents per share, on sales of $14.8 million during the three months ended Sept. 30.
That compares with profits of $172,000, or 1 cent per share, on sales of $11.1 million during the same period last year. Read more
Digirad swings to Q3 black
Digirad (NSDQ:DRAD) posted third-quarter profits on a 1.1 percent addition to its top line.
The company logged profits of $99,000, or 1 cent per share, on sales of $13.4 million for the three months ended Sept. 30.
That compares with losses of $1.3 million, or 7 cents per share, on sales of $13.3 million for the same period last year. Read more
Q3 sales flat for Iridex, profits plummet
Third-quarter sales for Iridex (NSDQ:IRIX) were flat but profits plummeted 61.6 percent.
Iridex reported profits of $349,000, or 3 cents per share, on sales of $10.8 million for the three months ended Oct. 1.
That compares with profits of $910,000, or 9 cents per share, on sales of $10.8 million during the same period last year. Read more
Novadaq’s Q3 sales plunge, but losses narrow 71%
Novadaq’s (TSE:NDQ) third-quarter sales were off by 33.1 percent, but the company still pared its net losses by 71.1 percent.
The company posted losses of $1.3 million, or 4 cents per share, on sales of $4.2 million for the three months ended Sept 30.
That compares with losses of $4.5 million, or 17 cents per share, on sales of $6.3 million during the same period last year. Read more
Viking Systems boost sales, cuts losses
Viking Systems (OTC:VKNG) boosted third-quarter sales by 61.8 percent and cut its losses 10.0 percent.
Viking reported losses of $569,000, or 1 cent per share, on sales of $3.0 million during the three months ended Sept. 30.
That compares with losses of $633,000, also 1 cent per share, on sales of $1.8 million during the same period last year. Read more